Centre Léon Bérard

Running trials

• Not yet recruiting

  Risk-reducing Strategies, Including Fimbriectomy, in Women With a Germline Mutation Predisposing to Ovarian or Pelvic Cancer

  NCT06726330· Source

• Not yet recruiting

  Bacterial Decolonization to Prevent Severe Radiation Dermatitis in Head and Neck Squamous Cell Carcinoma

  NCT07888907· Source

• Not yet recruiting

  Analysis of histological risk factors and biomarkers in paediatric retinoblastoma

  2024-515962-15-00· Phase 2· Source

• Not yet recruiting

  Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

  NCT07739459· Phase 2· Source

• Not yet recruiting

  Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy

  NCT07814001· Phase 2· Source

• Not yet recruiting

  Phase I Study Evaluating 161Tb-PSMA Therapy in Adult Patients With Metastatic Clear Cell Renal Cell Carcinoma

  NCT07828249· Phase 1· Source

• Recruiting

  Predicting Response to Anti-PD-1/PD-L1 Immunotherapy by Plasma Extracellular Vesicle Analysis

  NCT07376512· Source

• Not yet recruiting

  Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets

  NCT07234877· Phase 2· Source

• Not yet recruiting

  Biomarker Investigation for Early Gastric Cancer Detection

  NCT07884669· Source

• Not yet recruiting

  DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

  NCT07707895· Phase 1/2· Source

• Recruiting

  Phase 3 Study of Azenosertib Versus Chemotherapy in Platinum-Resistant Ovarian Cancers Positive for Cyclin E1 Protein Expression

  2025-524641-27-00· Phase 3· Source

• Recruiting

  A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)

  NCT07700758· Phase 2· Source

• Not yet recruiting

  A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors

  2024-518348-19-00· Phase 1· Source

• Recruiting

  Phase 3 Study of Investigator Choice of Chemotherapy with or without Zoldonrasib as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma

  2025-524928-21-00· Phase 3· Source

• Recruiting

  Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse

  NCT07871864· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

  NCT07541170· Phase 3· Source

• Not yet recruiting

  Phase 3 Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC 6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

  2025-524969-24-00· Phase 3· Source

• Recruiting

  A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)

  NCT07843940· Phase 1/2· Source

• Not yet recruiting

  Relacorilant and Nab-Paclitaxel in Recurrent or Metastatic Cervical Cancer

  NCT07763496· Phase 2· Source

• Not yet recruiting

  Phase I/II trial of Dinutuximab beta in combination with Irinotecan and Rapamycin in pediatric, adolescents and adult patients with relapsed/refractory bone tumors. BONE DINIRRA

  2026-525463-40-00· Phase 1/2· Source

• Not yet recruiting

  Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.

  NCT07717450· Phase 3· Source

• Recruiting

  A phase 1/2a, first-in-human, open-label, dose-escalating study with a safety expansion cohort to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumour activity of TAX2 in patients with relapsed/refractory advanced/metastatic solid tumours

  2025-521164-36-00· Phase 1/2· Source

• Not yet recruiting

  Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.

  NCT07340619· Phase 2· Source

• Recruiting

  A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

  NCT07701941· Phase 1/2· Source

• Recruiting

  Functional Lung Avoidance Planning Guided by Lung Perfusion PET/CT Versus Anatomical Planning for Lung Stereotactic Body Radiotherapy

  NCT07289646· Phase 3· Source

• Not yet recruiting

  Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer

  NCT07151586· Phase 2· Source

• Not yet recruiting

  Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL).

  NCT07624799· Phase 2· Source

• Not yet recruiting

  Superior Mesenteric Artery First Versus Standard Approach in Pancreaticoduodenectomy

  NCT07547033· Source

• Not yet recruiting

  Reduction of treatment after Complete Response in Advanced Hormone-Sensitive Breast Cancer

  2026-526319-12-00· Phase 3· Source

• Not yet recruiting

  Prospective evaluation of response to treatment by analysis of measurable residual disease in younger adult patients (18-60 years) with acute myeloid leukemia (AML). The Backbone InterGroup (BIG)-2 umbrella trial from the Acute Leukemia French Intergroup (ALFA, FILO) - BIG2

  2026-525759-96-00· Phase 4· Source

• Not yet recruiting

  Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases

  NCT07359456· Phase 2· Source

• Recruiting

  A study to find out if enfortumab vedotin given with pembrolizumab helps people with muscle-invasive bladder cancer keep their bladder.

  2025-524488-18-00· Phase 2· Source

• Recruiting

  A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

  NCT07566052· Phase 3· Source

• Not yet recruiting

  Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer.

  2026-525883-17-00· Phase 3· Source

• Recruiting

  A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer

  NCT07693751· Phase 1/2· Source

• Not yet recruiting

  Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

  NCT07747506· Phase 2· Source

• Recruiting

  BGB-43395 in Combination with Letrozole versus CDK4/6i with Letrozole for Patients with Previously Untreated Advanced or Metastatic HR+/HER2- Breast Cancer

  NCT07492641· Phase 3· Source

• Not yet recruiting

  Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer

  NCT07637851· Phase 1/2· Source

• Not yet recruiting

  A Phase 2 Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

  2025-523923-22-00· Phase 2· Source

• Recruiting

  Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)

  2023-505575-69-01· Phase 3· Source

• Active, not recruiting

  Open-Label Extension Study to Provide Continued Access to Avutometinib Alone or in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

  2025-524713-88-00· Phase 2· Source

• Recruiting

  A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer

  NCT07673887· Phase 3· Source

• Recruiting

  A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

  NCT07659782· Phase 2· Source

• Recruiting

  A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)

  NCT07630974· Phase 1/2· Source

• Recruiting

  Phase II study of ficerafusp alfa in combination with nivolumab in patients with platinum-refractory head and neck squamous cell carcinoma who progressed within 6 months of multimodality therapy for locally advanced disease.

  2025-521437-88-00· Phase 2· Source

• Recruiting

  Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

  NCT07476287· Phase 2· Source

• Not yet recruiting

  Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers

  NCT07437287· Phase 2/3· Source

• Not yet recruiting

  MOST-Express – A phase II, multicenter, open-label, personalized medicine, tumor agnostic platform trial evaluating the anti-tumor activity of antibody-based therapies in metastatic cancer patients.

  2025-522058-38-00· Phase 2· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)

  2025-523997-18-00· Phase 1/2· Source

• Recruiting

  A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer

  2025-522818-23-00· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer77 recruiting
• Childhood cancers46 recruiting
• Colorectal cancer39 recruiting
• Ovarian cancer36 recruiting
• Metastatic breast cancer35 recruiting
• Sarcoma32 recruiting
• Pancreatic cancer29 recruiting
• Gastric and esophageal cancer26 recruiting
• Prostate cancer26 recruiting
• Endometrial cancer24 recruiting
• Liver and biliary tract cancer20 recruiting
• Head and neck cancer19 recruiting
• Triple-negative breast cancer19 recruiting
• Bladder cancer15 recruiting
• Melanoma15 recruiting
• Kidney cancer11 recruiting
• Cervical cancer9 recruiting
• Chronic lymphocytic leukaemia9 recruiting
• Multiple myeloma8 recruiting
• Neuroendocrine tumours8 recruiting
• Diffuse large B-cell lymphoma6 recruiting
• Myeloproliferative neoplasms5 recruiting
• Acute lymphoblastic leukaemia4 recruiting
• Follicular lymphoma4 recruiting
• Neuroblastoma4 recruiting
• Chronic myeloid leukaemia3 recruiting
• Mantle cell lymphoma3 recruiting
• Thyroid cancer3 recruiting
• Acute myeloid leukemia2 recruiting
• Glioblastoma2 recruiting
• Mesothelioma2 recruiting
• Hodgkin lymphoma1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Phase 1 Study of ATV-1601, in Patients with Advanced Cancer that have AKT1 E17K Mutations

  2025-521480-12-00· Phase 1· Source

• Active, not recruiting

  Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer

  2025-521115-40-00· Phase 2· Source

• Not yet recruiting

  Evaluation of Efficacy and Safety De-escalation Versus Standard Adjuvant Chemotherapy in Patients With Low Risk Localized Gastroesophageal Adenocarcinoma

  NCT06933966· Phase 2· Source

• Recruiting

  Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib

  NCT06620835· Phase 2· Source

• Active, not recruiting

  Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)

  NCT06898957· Phase 1· Source

• Completed

  A Study to see How Well and How Safely Different Treatments Work in a Group of Patients with Non-Small Cell Lung Cancer, Chosen Based on their Biomarker Status

  2024-511239-91-00· Phase 2· Source

• Recruiting

  A Randomized, Double-Blind, Placebo-Controlled, MultiRegional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy

  2023-507097-41-01· Phase 3· Source

• Active, not recruiting

  Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer

  NCT06840483· Phase 2· Source

• Completed

  N/A

  2024-513121-22-00· Phase 2· Source

• Completed

  A study to find a suitable dose of BI 765883 and to test whether it helps people with advanced pancreatic cancer when taken alone or together with chemotherapy

  2023-508998-85-00· Phase 1· Source

• Active, not recruiting

  Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)

  NCT06632951· Phase 2· Source

• Completed

  A phase I study of [177Lu]Lu-EVS459 in patients with ovarian and lung cancers

  2023-507674-41-00· Phase 1· Source

• Completed

  Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

  NCT06433219· Phase 2· Source

• Active, not recruiting

  A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

  NCT06607185· Phase 1· Source

• Terminated

  LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)

  NCT06558799· Phase 2· Source

• Completed

  FERtility After Therapy With Intensive Lymphoma in Young Women: LNH-03 1B, LNH-03 2B, LNH-07 3B, GAINED Follow-up

  NCT06592846· Source

• Terminated

  Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]

  NCT06150040· Phase 1/2· Source

• Completed

  Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in France

  NCT06735781· Source

• Completed

  Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer: a French Multicentric Retrospective Early Access Program-based Study

  NCT06599463· Source

• Terminated

  Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment

  NCT06505018· Source

• Completed

  Effects of maintenance cabozantinib+BSC versus BSC in children and AYA with osteosarcoma. ( CabOSTar )

  NCT06341712· Phase 2· Source

• Withdrawn

  Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures

  NCT06084689· Phase 2· Source

• Completed

  EPI-7386 in Combination with Enzalutamide versus Enzalutamide alone in Metastatic Castration-Resistant Prostate Cancer

  NCT05075577· Phase 1/2· Source

• Recruiting

  [18F]PSMA-1007 PET CT in patients with newly-diagnosed prostate cancer

  2023-504026-19-01· Phase 3· Source

• Active, not recruiting

  Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma

  NCT05739942· Phase 1· Source

• Completed

  Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

  NCT05652868· Phase 1/2· Source

• Completed

  A Phase 2 Trial of BDC-1001 as Single Agent and in Combination with Pertuzumab in Subjects with Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Previously Treated with Trastuzumab Deruxtecan

  NCT05954143· Phase 2· Source

• Completed

  FIH study of ALE.C04 anti-CLDN1 mAb monotherapy or in combination with pembrolizumab in patients with R/M HNSCC

  2023-505145-93-00· Phase 1/2· Source

• Active, not recruiting

  A phase I, open-label, multi-center study of KFA115 as a single agent and in combination with pembrolizumab in patients with select advanced cancers

  2022-502381-25-01· Phase 1· Source

• Completed

  A trial to find out if vidutolimod together with cemiplimab is safe and if it works in adult participants with advanced cancer or metastatic cancer

  NCT04916002· Phase 2· Source

• Withdrawn

  Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

  NCT05743270· Phase 2· Source

• Completed

  (VELA) Study of BLU-222 in Advanced Solid Tumors

  NCT05252416· Phase 1/2· Source

• Completed

  Multicentre Retrospective Cohort Study of Palliative Care Pathways in Patients Who Died From Sarcoma

  NCT07532668· Source

• Active, not recruiting

  A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)

  NCT06099782· Phase 2· Source

• Completed

  A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma.

  NCT04718675· Phase 1· Source

• Completed

  An Open-Label Multicenter Phase 1b Study of Tolinapant (ASTX660) in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Patients With Rectum Cancer (PRAAR 1: Preoperative Radiotherapy And ASTX660 in Rectum Cancer)

  2024-511963-28-00· Phase 1· Source

• Completed

  Study Evaluating the Safety and Efficacy of MEDI5752 in Combination With Stereotactic Radiotherapy in Patients With Metastatic Sarcoma

  NCT05821231· Phase 1· Source

• Completed

  Randomized, non-comparative, open-label early phase Ib study with OBT076 or OBT076 followed by Balstilimab in patients with Adenoid Cystic Carninoma of the Head and Neck

  2023-503270-20-00· Phase 1· Source

• Recruiting

  Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted Therapy

  NCT06130787· Source

• Active, not recruiting

  A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

  NCT06003231· Phase 2· Source

• Completed

  Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients With Metastatic Clear Cell Renal Cancer

  NCT06059014· Phase 1/2· Source

• Terminated

  Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib

  NCT05625087· Phase 2· Source

• Completed

  A Study of NB003 in Patients With Advanced Malignancies

  NCT04936178· Phase 1/2· Source

• Completed

  Detection of tumor DNA in the blood of patients receiving standard therapy for hormone receptorpositive (HR+) non-HER2 expressing (HER2-) metastatic breast cancer as a tool to select those who may benefit from the next course of fulvestrant in combination with alpelisib or ribociclib.

  2022-502372-22-01· Phase 2· Source

• Terminated

  Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer

  NCT05932667· Phase 2· Source

• Completed

  Milademetan and fulvestrant in GATA3-mutant, ER-positive, HER2-negative advanced or metastatic breast cancer patients (DEMETER)

  2022-502360-21-00· Phase 2· Source

• Completed

  Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)

  NCT06036836· Phase 2· Source

• Completed

  A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT05848011· Phase 2· Source

• Completed

  A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

  NCT05665530· Phase 1· Source

• Completed

  Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

  2022-502196-31-00· Phase 2/3· Source

Trial sites

• Centre Leon Berard0 trials
• Center Leon Berard0 trials
• Centre Berard Leon1 trial
• Centre de Lutte Contre le Cancer Centre Leon Berard1 trial
• Centre de lutte contre le cancer Léon Bérard1 trial
• Centre de Lutte Contre le Cancer Leon Bérard Lyon1 trial
• Centre Leon Berard804 trials
• Centre Léon Bérard, Centre de lutte contre le cancer0 trials
• Centre Léon BERARD de Lyon1 trial
• CENTRE LEON BERARD; Département d?Hématologie et d?Oncologie1 trial
• Centre Leon Berard - departement d'oncologie medicale1 trial
• Centre Leon Berard; Departement Oncologie Medicale1 trial
• Centre Léon Bérard - Hématologie3 trials
• Centre Leon Berard /ID# 1626631 trial
• Centre Leon Berard /ID# 1700181 trial
• Centre Leon Berard /ID# 2051070 trials
• Centre Leon Berard /ID# 2179101 trial
• Centre Leon Berard /ID# 2185151 trial
• Centre Leon Berard /ID# 2303480 trials
• Centre Leon Berard /ID# 2509870 trials
• Centre Leon Berard /ID# 2673970 trials
• Centre Leon Berard /ID# 2694180 trials
• Centre Leon Berard /ID# 2698481 trial
• Centre Leon Berard /ID# 2706050 trials
• Centre Leon Berard /ID# 2767100 trials
• Centre Leon Berard /ID# 2805750 trials
• Centre Léon Bérard, Institut d?Hémato-Oncologie Pédiatrique1 trial
• Centre Léon Bérard Lyon4 trials
• Centre Léon Bérard - Oncologie Médicale1 trial
• Centre Leon Berard - Service d'Oncologie0 trials
• Centre Leon Berard - Service d'Oncologie Medicale3 trials
• Centre Leon Berard - Service Oncologie Médicale1 trial
• Centre Leon Berard (Site 0244)1 trial
• Centre Leon-Berard (Site 0326)0 trials
• Centre Leon Berard (Site 0405)1 trial
• Centre Leon Berard (Site 0422)1 trial
• Centre Leon Berard (Site 0459)1 trial
• Centre Leon Berard (Site 0465)0 trials
• CENTRE LEON BERARD (Site 0900)1 trial
• Centre Leon Berard (Site 0904)0 trials
• CENTRE LEON BERARD (Site 0919)0 trials
• CENTRE LEON BERARD (Site 1101)0 trials
• CENTRE LEON BERARD (Site 1351)0 trials
• CENTRE LEON BERARD (Site 1401)0 trials
• Centre Leon Berard (Site 1901)1 trial
• CENTRE LEON BERARD (Site 3004)1 trial
• Centre Leon-Berard (Site 3100)0 trials
• CENTRE LEON BERARD (Site 4100)0 trials
• CTR Leon Berard3 trials
• Département d'Hématologie et Oncologie, Centre Léon Bérard1 trial
• Leon Berard Center4 trials
• Lyon - Centre Léon Bérard5 trials
• Service de Chirurgie Digestive, Centre Léon Bérard - Lyon1 trial
• The Centre Léon Bérard1 trial
• The Leon Berard Center0 trials
• Centre Léon Bérard0 trials
• Centre Léon Bérard2 trials
• Centre Leon Berard4 trials
• CENTRE LEON BERARD (Site 0151)1 trial
• CENTRE LEON BERARD (Site 0305)1 trial
• CENTRE LEON BERARD (Site 0459)0 trials
• CENTRE LEON BERARD (Site 1300)0 trials
• CENTRE LEON BERARD (Site 1305)0 trials
• CENTRE LEON BERARD (Site 1505)0 trials
• CENTRE LEON BERARD (Site 2004)0 trials
• Centre Leon Berard1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Lung cancer214 works · 200 trials
• Ovarian cancer160 works · 86 trials
• Sarcoma75 works · 82 trials
• Metastatic breast cancer29 works · 79 trials
• Triple-negative breast cancer27 works · 48 trials
• Endometrial cancer21 works · 47 trials
• Head and neck cancer17 works · 66 trials
• Neuroblastoma16 works · 12 trials
• Chronic myeloid leukaemia14 works · 10 trials
• Childhood cancers10 works · 99 trials
• Mesothelioma6 works · 11 trials
• Spinal muscular atrophy5 works · 0 trials